CONTEXT: The percentage of cancer patients > or =80 years old is expected to increase in the next few years. However data on the use of chemotherapy in these patients are limited. OBJECTIVE: We conducted a retrospective review to define the profile of patients > or =80 years old who received chemotherapy at our center and assess their survival. DESIGN, SETTING AND PARTICIPANTS: Patients > or =80 years treated with chemotherapy between 1 January 2000 and 31 December 2004 were included in this analysis. RESULTS: Of the 4689 patients treated with chemotherapy over the 5-year period, 133 patients (3%) were > or =80 years old. The median age was 83 years. 61% were females and 39% were males. 16% had hematologic tumors and 84% had solid tumors. Gynecological (32%) and aerodigestive cancers (27%) were the most common sites and lung cancer (22%) was the most common cancer. During the first regimen, 512 cycles of chemotherapy were delivered with a median of 3 cycles (range: 1-24 cycles). 49% received single and 51% multidrug regimens. Carboplatin was the most common single agent and carboplatin and paclitaxel was the most common combination among solid tumor patients. 19% of solid tumor patients received radiation with chemotherapy. The 1-year survival among hematologic cancer and solid tumor patients was 65% and 48%, respectively. Stage of disease was the only statistically significant factor predicting survival. CONCLUSIONS: In cancer patients > or =80 years old selected for chemotherapy, both single and multi-agent therapy appeared to be feasible.
CONTEXT: The percentage of cancerpatients > or =80 years old is expected to increase in the next few years. However data on the use of chemotherapy in these patients are limited. OBJECTIVE: We conducted a retrospective review to define the profile of patients > or =80 years old who received chemotherapy at our center and assess their survival. DESIGN, SETTING AND PARTICIPANTS: Patients > or =80 years treated with chemotherapy between 1 January 2000 and 31 December 2004 were included in this analysis. RESULTS: Of the 4689 patients treated with chemotherapy over the 5-year period, 133 patients (3%) were > or =80 years old. The median age was 83 years. 61% were females and 39% were males. 16% had hematologic tumors and 84% had solid tumors. Gynecological (32%) and aerodigestive cancers (27%) were the most common sites and lung cancer (22%) was the most common cancer. During the first regimen, 512 cycles of chemotherapy were delivered with a median of 3 cycles (range: 1-24 cycles). 49% received single and 51% multidrug regimens. Carboplatin was the most common single agent and carboplatin and paclitaxel was the most common combination among solid tumorpatients. 19% of solid tumorpatients received radiation with chemotherapy. The 1-year survival among hematologic cancer and solid tumorpatients was 65% and 48%, respectively. Stage of disease was the only statistically significant factor predicting survival. CONCLUSIONS: In cancerpatients > or =80 years old selected for chemotherapy, both single and multi-agent therapy appeared to be feasible.
Authors: Jacobien C Verhave; Pierre Fesler; Jean Ribstein; Guilhem du Cailar; Albert Mimran Journal: Am J Kidney Dis Date: 2005-08 Impact factor: 8.860
Authors: Albert J ten Tije; Jaap Verweij; Michael A Carducci; Wilfried Graveland; Theresa Rogers; Tatjana Pronk; M P Verbruggen; Fitzroy Dawkins; Sharyn D Baker Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: Stuart M Lichtman; Donna Hollis; Antonius A Miller; Gary L Rosner; Chris A Rhoades; Eric P Lester; Frederick Millard; John Byrd; Stephen A Cullinan; D Marc Rosen; Robert A Parise; Mark J Ratain; Merrill J Egorin Journal: J Clin Oncol Date: 2006-03-27 Impact factor: 44.544
Authors: Joseph M Unger; Charles A Coltman; John J Crowley; Laura F Hutchins; Silvana Martino; Robert B Livingston; John S Macdonald; Charles D Blanke; David R Gandara; E David Crawford; Kathy S Albain Journal: J Clin Oncol Date: 2005-12-05 Impact factor: 44.544
Authors: R Bruno; D Hille; A Riva; N Vivier; W W ten Bokkel Huinnink; A T van Oosterom; S B Kaye; J Verweij; F V Fossella; V Valero; J R Rigas; A D Seidman; B Chevallier; P Fumoleau; H A Burris; P M Ravdin; L B Sheiner Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: Hyman B Muss; Donald A Berry; Constance Cirrincione; Daniel R Budman; I Craig Henderson; Marc L Citron; Larry Norton; Eric P Winer; Clifford A Hudis Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544